到2050年,亚洲面临7 000亿美元来自抗微生物抗药性的威胁,超过癌症这一顶级杀手。 Asia faces a $700 billion threat from antimicrobial resistance by 2050, surpassing cancer as top killer.

影响投资和做法中心和世界经济论坛的一份新报告强调指出,亚洲抗微生物抗药性的威胁日益增大,到2050年,这种威胁可能耗资多达7 000亿美元,超过癌症,而癌症是造成死亡的主要原因。 A new report by the Centre for Impact Investing and Practices and the World Economic Forum highlights the growing threat of antimicrobial resistance (AMR) in Asia, which could cost up to $700 billion by 2050 and surpass cancer as the leading cause of death. 报告建议在改进知识、加强保健系统、加强监测和研究新的抗微生物剂方面进行跨部门投资。 The report recommends cross-sector investment in improving knowledge, strengthening health systems, enhancing surveillance, and researching new antimicrobials. 它强调采用统一的方法来对抗 AMR 并防止经济和健康危机。 It emphasizes a unified approach to combat AMR and prevent economic and health crises.